Abstract 454P
Background
Deep Vein Thrombosis and Pulmonary Embolism have been associated with significant morbidity and mortality worldwide. The risk of developing lower limb Deep Vein Thrombosis may be associated with cancer-related, patient, and treatment-related risk factors. Although the association between cancer and venous thromboembolism is well known, there is a paucity of information in Asian patients with respect to cancer-associated thrombosis.
Methods
This prospective, observational study was conducted at Artemis Hospital, Gurugram, a Tertiary Health Care Center in (Northern) India. We identified all the consecutive patients with histologically confirmed newly diagnosed Stage III/IV solid tissue malignancies between June 2021 and May 2022. Duplex Doppler Ultrasound of the bilateral lower limb was performed to determine the prevalence of Deep Vein Thrombosis. Data on clinical and tumor characteristics were collected and compared among patients with and without lower limb Deep Vein Thrombosis.
Results
A total of 100 patients were enrolled in the study. On Duplex Doppler venous ultrasound, the prevalence of lower limb deep vein thrombosis was 14%. An adjusted multivariable regression analysis showed that advanced stage (p=0.008), leukocytosis(p=0.042), OR[1.0],95% CI(1.00,1.2), deranged coagulation profile (Raised APTT, PT)(p=0.01),OR [1.74], 95%CI(1.14,2.679) hypercholesterolemia(p=0.007), OR[1.02], 95%CI (1.004,1.05) were independent predictors of Deep vein Thrombosis. The highest prevalence of venous thromboembolism was for pancreatic (2%) and lung cancer (2%).
Conclusions
Cancer-related thrombosis has to bear in treatment outcomes as well as morbidity and mortality. Routine lower-extremity Venous Doppler Ultrasonographic screening is useful for early detection and management at an initial evaluation of stage III/IV solid malignancies. There is a paucity of data on Indian patients. This is the first study conducted in the Indian subcontinent that has identified high-risk factors and prevalence of venous thromboembolism. Such study design will help us in formulating national-level guidelines for prophylaxis of cancer-associated thrombosis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
439P - Evaluating Ewing’s sarcoma as the prototype for cancer care in teenage and young adults (TYA): A single-center retrospective cross-sectional study
Presenter: Pradeep Kumar Kistampally
Session: Poster viewing 06
440P - Targeting KRAS<sup>G12C</sup>: Repurposing of potential therapeutics for the treatment of pancreatic ductal adenocarcinoma (PDAC)
Presenter: EVA RAHMAN KABIR
Session: Poster viewing 06
441P - Malignant diseases diagnosed in people living with HIV in Japan
Presenter: Kenju Ando
Session: Poster viewing 06
442P - Dose intensity and tolerance of modified FOLFIRINOX in patients with advanced cancer
Presenter: Tejaswini Adadadara
Session: Poster viewing 06
444P - Incidence of cancer diagnosis and cancer care before and after the COVID-19 pandemic in French Polynesia TEAHUPOO study
Presenter: Elodie HIRIGOYEN
Session: Poster viewing 06
445P - Development of a simple and objective prognostication model in patients with advanced solid malignant tumor treated with immune checkpoint inhibitors: A pan-cancer analysis
Presenter: Yuto Matsushita
Session: Poster viewing 06
446P - Impact of previous immunotherapy on chemotherapy efficacy in metastatic melanoma
Presenter: Meiyu Fang
Session: Poster viewing 06
447P - Clinical characteristics of 21 patients with type 1 diabetes mellitus related to immune checkpoint inhibitors
Presenter: Haruna Kameoka
Session: Poster viewing 06
448P - Prevalence of thyroid dysfunction, diabetes, and impact of palliative chemotherapy in advanced metastatic cancer patients: Prospective data from LMIC
Presenter: Amit Sehrawat
Session: Poster viewing 06
449P - The study of androgen receptor status in triple negative breast cancer patients at Medical Oncology Department, Yangon General Hospital (YGH)
Presenter: Khin Mu
Session: Poster viewing 06